Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

992
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
992
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

941
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
941
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

479
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
479
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

556
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
556
Lung Capacity01:47

Lung Capacity

56.2K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

663
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
663

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute exacerbation in fibrotic interstitial lung disease: An International Working Group Report.

American journal of respiratory and critical care medicine·2026
Same author

Impact of Excluding Anti-HLA-C and -DP Antibodies From the Allocation System on Kidney Transplant Access.

HLA·2026
Same author

Real-world persistence with antifibrotic treatments: a nationwide study on claims data in France (The REPEAT study).

Respiratory research·2026
Same author

Lung disease in rheumatoid arthritis.

Nature reviews. Rheumatology·2026
Same author

Systems serology identifies FcR-related autoantibody signatures and functions for Sjögren's syndrome.

EMBO molecular medicine·2026
Same author

Progressive pulmonary fibrosis: a state-of-the-art review.

The European respiratory journal·2026

Related Experiment Video

Updated: Jan 24, 2026

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis
04:01

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis

Published on: June 14, 2024

1.4K

Lung Diseases in Inflammatory Myopathies.

Thomas Barba1, Sabine Mainbourg2, Mouhamad Nasser3

  • 1Department of Internal Medicine, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France.

Seminars in Respiratory and Critical Care Medicine
|May 29, 2019
PubMed
Summary

Interstitial lung disease (ILD) affects most patients with inflammatory myopathy, causing significant mortality. Early diagnosis and risk stratification using autoantibodies are crucial for managing this severe lung complication.

More Related Videos

Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration
07:03

Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration

Published on: May 4, 2017

71.9K
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling
05:47

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

22.0K

Related Experiment Videos

Last Updated: Jan 24, 2026

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis
04:01

Author Spotlight: Advanced Integrated Model for Sepsis-Induced Myopathy and Single-Cell Metabolic Analysis

Published on: June 14, 2024

1.4K
Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration
07:03

Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration

Published on: May 4, 2017

71.9K
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling
05:47

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

22.0K

Area of Science:

  • Rheumatology
  • Pulmonology
  • Immunology

Background:

  • Lung involvement is the primary cause of mortality in inflammatory myopathy.
  • Interstitial lung disease (ILD) affects approximately 75% of patients, significantly impacting morbidity and mortality.
  • Accurate classification of inflammatory myopathy phenotypes and risk stratification for lung involvement are essential.

Purpose of the Study:

  • To review the clinical approach to diagnosing and managing interstitial lung disease (ILD) in patients with inflammatory myopathy.
  • To highlight the role of myositis-associated autoantibodies in classifying disease phenotypes and predicting ILD risk.
  • To discuss current and emerging treatment strategies for ILD in inflammatory myopathy.

Main Methods:

  • Review of clinical manifestations, serologic findings (myositis-associated autoantibodies), and diagnostic tools for ILD in inflammatory myopathy.
  • Analysis of high-resolution computed tomography (HRCT) patterns and diagnostic procedures like bronchoalveolar lavage.
  • Examination of treatment approaches, including corticosteroids, immunosuppressive therapy, and novel agents like rituximab.

Main Results:

  • The antisynthetase syndrome, particularly with non-anti-Jo1 antibodies (e.g., anti-PL7, anti-PL12), is associated with a 70% risk of ILD.
  • Nonspecific interstitial pneumonia and organizing pneumonia are common HRCT patterns in inflammatory myopathy-associated ILD.
  • Rituximab shows promise in retrospective studies for refractory or rapidly progressive ILD, with ongoing trials evaluating its impact on mortality.

Conclusions:

  • Early identification and risk stratification of ILD in inflammatory myopathy are critical for patient outcomes.
  • While lung biopsy is generally discouraged, specific autoantibody profiles aid in predicting ILD risk.
  • Current treatment involves corticosteroids and immunosuppressants, with rituximab offering a potential option for severe cases, pending further clinical validation.